Analysts Offer Predictions for ITOS FY2029 Earnings

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share estimates for iTeos Therapeutics in a research note issued to investors on Thursday, March 6th. HC Wainwright analyst S. Ramakanth forecasts that the company will earn $1.19 per share for the year. HC Wainwright currently has a “Buy” rating and a $46.00 target price on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($3.49) per share.

A number of other research analysts also recently issued reports on ITOS. JPMorgan Chase & Co. decreased their target price on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday. Wells Fargo & Company decreased their price objective on iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday. Finally, Wedbush reaffirmed an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a report on Wednesday.

iTeos Therapeutics Price Performance

ITOS stock opened at $7.05 on Friday. The company has a market capitalization of $257.56 million, a P/E ratio of -2.24 and a beta of 1.38. iTeos Therapeutics has a 12 month low of $6.67 and a 12 month high of $18.75. The firm’s fifty day simple moving average is $7.52 and its 200-day simple moving average is $9.48.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.13.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Creative Planning boosted its stake in shares of iTeos Therapeutics by 6.5% during the 3rd quarter. Creative Planning now owns 19,636 shares of the company’s stock worth $200,000 after acquiring an additional 1,196 shares in the last quarter. SG Americas Securities LLC raised its holdings in iTeos Therapeutics by 12.2% in the 4th quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock worth $106,000 after purchasing an additional 1,508 shares during the period. Wells Fargo & Company MN boosted its position in iTeos Therapeutics by 16.9% during the fourth quarter. Wells Fargo & Company MN now owns 16,644 shares of the company’s stock worth $128,000 after purchasing an additional 2,402 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in iTeos Therapeutics in the third quarter valued at approximately $31,000. Finally, Virtus ETF Advisers LLC grew its holdings in iTeos Therapeutics by 58.2% in the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock valued at $69,000 after purchasing an additional 3,293 shares during the period. Hedge funds and other institutional investors own 97.16% of the company’s stock.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.